SEC Form 4 · accession 0000899243-18-007329

Emergent BioSolutions Inc. · EBS

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Chairman · Director · 10% Owner

Period of report

Mar 9, 2018

Accepted (ET)

Mar 13, 2018 · 9:23 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001367644

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1	Mar 9, 2018	M	13,237	—	A	1,558,217	D
Common Stock	Mar 9, 2018	F	3,224	$51.84	D	1,554,993	D
Common Stock^F2	holding	—	—		—	4,344,250	I	By Intervac, L.L.C.
Common Stock^F3	holding	—	—		—	1,524,155	I	By Biovac, L.L.C.

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Restrictive Stock Units^F1,F4	—	Mar 9, 2018	M	13,237	D	—	—	Common Stock	13,237	48,598	D

F1Restricted stock units convert into common stock on a one-for-one basis.
F2Mr. El-Hibri's wife, individually, and Mr. and Mrs. El-Hibri, as tenants by the entirety, collectively hold an aggregate 40.65% equity interest in Intervac, L.L.C., which in turn is the direct owner of 4,344,250 shares of the Issuer's common stock. Mr. El-Hibri disclaims beneficial ownership of the shares of the Issuer's common stock directly owned by Intervac, L.L.C. for purposes of Section 16 of the Exchange Act or otherwise, except to the extent of his pecuniary interest therein.
F3Mr. El-Hibri, individually, and Mr. and Mrs. El-Hibri, as tenants by the entirety, collectively hold an aggregate 89.2% equity interest in Biovac, L.L.C, which in turn is the direct owner of 1,524,155 shares of the Issuer's common stock. Mr. El-Hibri disclaims beneficial ownership of the shares of the Issuer's common stock directly owned by Biovac, L.L.C. for purposes of Section 16 of the Exchange Act or otherwise, except to the extent of his pecuniary interest therein.
F4On March 10, 2015, Mr. El-Hibri was granted 39,709 restricted stock units (after giving effect to the adjustment in connection with the Issuer's spin-off of Aptevo Therapeutics Inc.) vesting in three equal annual installments beginning on the day prior to the anniversary of the grant date.